MK-677 Ibutamoren: Ghrelin Receptor Mechanism and Research Guide

MK-677 (Ibutamoren) is a non-peptide ghrelin receptor agonist investigated in preclinical and early clinical research for its ability to stimulate growth hormone (GH) secretion and elevate IGF-1 levels in animal models and human volunteers. It is not approved by the FDA for human or veterinary use. Research on MK-677 is ongoing, findings remain largely exploratory, and no long-term human safety profile has been established.

Most compounds that influence growth hormone do so through injectable peptide routes — complex, unstable, and difficult to standardize in a laboratory setting. MK-677 is different. It is a small-molecule, orally active ghrelin mimetic, meaning it activates the growth hormone secretagogue receptor (GHSR-1a) via the same pathway triggered by the hunger-signaling peptide ghrelin — but without requiring injection or peptide chain stability.

That distinction has made MK-677 one of the more frequently referenced compounds across preclinical GH-axis research. When researchers need a reliable, orally deliverable tool to stimulate pulsatile GH release in laboratory models, MK-677 keeps appearing in the literature. It has also accumulated one of the more substantial early-phase clinical investigation records among non-approved GH-related research compounds, which makes it an unusually well-documented subject for a compound that remains outside approved use.

This article provides a structured lab overview of MK-677 Ibutamoren — its molecular identity, receptor mechanism, what preclinical and early clinical investigations have examined, how it compares to other GH secretagogues, and the full risk and compliance picture that any researcher or research-following reader needs to understand before engaging with this compound.

Disclaimer: MK-677 (Ibutamoren) is a research compound not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use. It is not a dietary supplement or consumer product, and it is not intended to diagnose, treat, cure, or prevent any disease. This content is for informational purposes only. Always consult a licensed medical professional before making any health-related decisions.

What Is MK-677 Ibutamoren at the Molecular Level?

MK-677 is a non-peptide, orally bioavailable growth hormone secretagogue (GHS) with the molecular formula C₂₇H₃₆N₄O₅S and a molecular weight of 528.66 g/mol. Its CAS number is 159634-47-6, indexed under PubChem CID 9918684 (ibutamoren mesylate salt form); the free base form is indexed at CID 9912089.

Also referenced in the literature under the names Ibutamoren mesylate, MK-0677, and L-163,191, the compound was originally developed by Merck & Co. as part of a broader program investigating orally active GH secretagogues during the 1990s. Structurally, MK-677 belongs to the spiroindoline compound class — a specific non-peptide scaffold that enables GHSR-1a engagement without the stability constraints of peptide-based secretagogues like GHRP-6 or GHRP-2.

MK-677 Chemical Identity Quick Reference

Property	Detail
CAS Number	159634-47-6
Molecular Formula	C₂₇H₃₆N₄O₅S
Molecular Weight	528.66 g/mol
PubChem CID	9918684 (mesylate); 9912089 (free base)
Compound Class	Spiroindoline-derived non-peptide GHS
GHSR-1a Binding (Ki)	~0.4 nM
Oral Bioavailability	~60–70% (preclinical PK data)
Half-Life	~24 hours (human PK data)
Solubility	DMSO: ≥50 mg/mL; Water: limited
Storage	−20°C, desiccated, light-protected
WADA Status	Prohibited — S2 (2026)
Physical Form	White to off-white powder

Key molecular characteristics noted in the research literature:

• Spiroindoline-derived compound class — the specific structural scaffold that enables non-peptide GHSR-1a engagement
• Orally bioavailable at approximately 60–70% in pharmacokinetic studies — substantially higher than most peptide-based GH secretagogues, which require parenteral administration
• High selectivity for the GHSR-1a receptor — minimal reported cross-reactivity with other receptor populations in early binding studies
• Half-life of approximately 24 hours in human pharmacokinetic data from early investigational studies — significantly longer than most peptide GH secretagogues
• Molecular weight of 528.66 g/mol places it within the range of orally active drug candidates under Lipinski’s rule of five parameters

How Does MK-677 Work? The Ghrelin Receptor Mechanism Explained

MK-677 activates the growth hormone secretagogue receptor type 1a (GHSR-1a) — the same receptor targeted by the endogenous peptide ghrelin. Ghrelin is produced primarily in the stomach lining and signals to the hypothalamus and pituitary gland as part of the body’s hunger and energy-sensing cascade. Among its downstream effects in animal models, ghrelin signaling at GHSR-1a stimulates the release of growth hormone from the anterior pituitary.

MK-677 mimics this signaling interaction. By binding GHSR-1a with a Ki of approximately 0.4 nM — placing it among the highest-affinity synthetic GHSR-1a agonists characterized — it triggers a receptor-mediated cascade that results in GH secretion without requiring the presence of ghrelin itself.

The GH-IGF-1 Axis: What Gets Activated

Once GHSR-1a is activated by MK-677 in preclinical models, the downstream sequence observed in animal and early human research involves:

1. GHSR-1a activation → triggers Gq/11-coupled phospholipase C (PLC) activation → IP3 generation → intracellular calcium release → GH-containing vesicle exocytosis from pituitary somatotrophs
2. Hypothalamic GHRH release is potentiated — amplifying the natural GH pulse signal
3. Somatostatin suppression — MK-677 has been observed to partially reduce somatostatinergic tone, which normally inhibits GH release
4. Anterior pituitary GH secretion increases in a pulsatile pattern
5. Hepatic IGF-1 production rises in response to elevated GH — the primary downstream marker measured in published research

This dual mechanism — stimulating GHRH via the Gq/PLC/IP3/calcium cascade while partially suppressing somatostatin — is one reason researchers have described MK-677’s GH pulse pattern as more physiologically distributed than that seen with direct GH administration in laboratory models.

Receptor Binding Profile

In competitive binding assays, MK-677 demonstrates high binding affinity at GHSR-1a with a Ki of approximately 0.4 nM — placing it among the highest-affinity synthetic GHSR-1a agonists characterized. Functional assay EC₅₀ values in cellular systems are reported in the low nanomolar range depending on the assay design. Its selectivity profile at GHSR-1a versus other receptor families has been characterized as high in early binding panels — making it a preferred tool compound for GHSR-1a pathway studies.

What Has Research Investigated Regarding MK-677?

The following section summarizes observations from peer-reviewed preclinical and early human investigational literature. Findings from human volunteer studies are early-phase only and do not constitute clinical evidence of safety or approved efficacy for any indication.

GH and IGF-1 Elevation in Human Volunteer Studies

A 1996 study published in the Journal of Clinical Endocrinology & Metabolism by Chapman et al. examined oral MK-677 administration in healthy elderly subjects. The study reported a 97% increase in mean 24-hour GH concentrations and elevated IGF-1 into the normal young-adult range within two to four weeks — without changing GH pulse frequency, meaning MK-677 amplifies the physiological pattern of GH release rather than producing a sustained supraphysiological surge. These findings established MK-677 as one of the earliest peer-reviewed records of oral GH-axis modulation in humans under investigational conditions. These findings are investigational only. doi:10.1210/jcem.81.12.8954023. PMID: 8954023.

Body Composition and Lean Tissue Markers in Older Adults

A 2008 study published in Annals of Internal Medicine by Nass et al. investigated MK-677 in healthy older adults over 12 months. The study examined body composition metrics alongside GH pulsatility and IGF-1 data. Researchers observed changes in lean body mass markers alongside expected elevations in GH and IGF-1 — though the study also documented side effects including increased appetite, transient lower extremity edema, and one serious cardiovascular adverse event, underscoring the compound’s risk profile. These findings are investigational only.

Nitrogen Balance and Catabolic State Studies

A 1998 paper in the Journal of Clinical Endocrinology & Metabolism by Murphy et al. examined MK-677’s effects on nitrogen balance in diet-induced catabolic conditions in healthy volunteers. The study observed improvements in nitrogen retention markers in the MK-677 group compared to controls — data that has been referenced in subsequent GH secretagogue research examining metabolic state modulation. These remain early investigational findings only.

Fat-Free Mass and Energy Expenditure in Obese Subjects

Svensson et al. (1998) examined two months of MK-677 administration in obese subjects, reporting increased GH secretion, fat-free mass, and energy expenditure alongside expected IGF-1 elevation. These are early investigational observations only and do not constitute clinical evidence of efficacy for any indication. PMID: 9467549.

Bone Turnover Markers in Healthy and Functionally Impaired Elderly Adults

Murphy et al. (1999) examined MK-677’s effects on bone turnover in healthy and functionally impaired elderly adults, observing increases in osteocalcin and bone-specific alkaline phosphatase — biochemical markers used as proxies for bone remodeling activity in research settings. These are biomarker observations only and do not establish clinical outcomes. PMID: 10404823.

Sleep Architecture Studies

A subset of MK-677 research has examined its effects on sleep architecture in small investigational cohorts. Observations in early studies noted increases in REM sleep duration and slow-wave sleep markers — findings attributed to GH’s known role in sleep regulation. This remains a limited and exploratory area of investigation.

How Does MK-677 Compare to Other GH Secretagogues in Research?

Researchers working across the GH secretagogue class frequently reference MK-677 alongside peptide-based GHS compounds. Key distinctions observed in the preclinical and investigational literature:

• Oral bioavailability: Unlike GHRP-6, GHRP-2, and CJC-1295, MK-677 is orally active at approximately 60–70% bioavailability — eliminating the injection route and peptide stability variables that complicate laboratory dosing protocols. This is its primary practical advantage as a research tool compound.
• Half-life: MK-677’s approximately 24-hour half-life is substantially longer than most peptide GH secretagogues (GHRP-6 half-life: ~15–60 minutes). This makes it easier to maintain stable receptor engagement windows in in vivo study designs.
• Receptor selectivity: As a GHSR-1a selective agonist with a binding Ki of ~0.4 nM, MK-677’s receptor profile is more precisely defined than some stacked peptide combinations used in GH research, offering cleaner mechanistic attribution in single-compound study designs.
• Side effect profile in human volunteers: Unlike direct GH administration, which produces sustained supraphysiological GH levels, MK-677 in early human studies produced pulsatile GH patterns more consistent with endogenous release via the Gq/PLC/IP3/calcium pathway — though side effects including appetite increase, water retention, fasting insulin elevation, and a documented cardiovascular adverse event were observed.
• IGF-1 elevation magnitude: In published human volunteer data, MK-677 produced more sustained IGF-1 elevation than single-dose GHRP administrations, attributed to its longer half-life and continuous GHSR-1a engagement.

These comparisons are drawn from investigational literature and do not imply safety, efficacy, or approval for any use outside strictly controlled research settings.

What Are the Risks and Limitations of MK-677 Research?

This section is important reading for anyone following research on MK-677 Ibutamoren.

Handling Precautions: MK-677 should be handled by trained laboratory personnel only, in a controlled research environment. Appropriate PPE, including nitrile gloves and eye protection, is mandatory. Avoid direct skin contact, inhalation of powder during weighing, or mucosal exposure during preparation. Treat all research compound handling as potentially hazardous until a full safety profile is established.

Exposure Risks: MK-677 is a research compound thought to activate the ghrelin receptor (GHSR-1a) and stimulate pulsatile growth hormone release via the Gq/PLC/IP3/calcium cascade in preclinical models. No comprehensive human safety profile has been established beyond early-phase investigational data. Accidental human exposure during laboratory handling must be managed through standard institutional biosafety protocols.

Storage: Store MK-677 at −20°C in a sealed, desiccated, light-protected container for archival reference standards. For working stocks, controlled room temperature (15–25°C) away from direct light, heat, and humidity is acceptable for short-term use. Do not store near solvents or reagents that could compromise the compound’s structural integrity.

Toxicity and Data Limitations: No chronic toxicity data exist for MK-677 beyond limited early investigational studies in human volunteers, which were conducted over months, not years. Long-term effects on GH-axis regulation, insulin sensitivity, and endocrine function remain uncharacterized. All preclinical findings derive from short-duration models only.

Insulin Sensitivity and Metabolic Risk: Published early human volunteer studies documented transient elevations in fasting insulin and blood glucose in MK-677 groups — a finding consistent with GH’s known insulin-antagonizing effects. This metabolic risk is particularly relevant in research models involving subjects with pre-existing glucose regulation concerns and must be factored into study design ethics.

Cardiac Risk Signal — Documented in Clinical Data: The Nass et al. (2008) 12-month study documented cardiovascular-related concerns, including lower extremity edema and increased fasting insulin, and noted one serious cardiovascular adverse event in the study population. Merck’s broader MK-677 clinical development program was halted before Phase III for multiple indications, and the FDA has noted potential congestive heart failure risk in certain patient populations as a concern with sustained GH/IGF-1 axis activation. Researchers designing protocols involving MK-677 should treat cardiac safety as an unresolved and material risk, particularly in subjects with existing cardiovascular conditions.

Hormonal Axis Disruption Risk: Sustained activation of the GH-IGF-1 axis carries an uncharacterized risk of downstream feedback disruption. Elevated IGF-1 and GH pulsatility over extended periods may alter hypothalamic-pituitary regulatory set points. The magnitude and reversibility of this disruption from research-context exposure remain undefined.

Carcinogenicity and Tumor Promotion Concerns: IGF-1 is a known mitogenic signaling molecule. Sustained elevation of IGF-1 in laboratory models has been associated with increased proliferative signaling in cell line studies. No carcinogenicity studies for MK-677 exist in standard regulatory toxicology formats, but its IGF-1-elevating mechanism warrants careful consideration in any study design involving cancer biology or oncology research contexts.

Regulatory and IACUC Compliance: MK-677 is not approved by the FDA or any major regulatory body for human or veterinary use. It is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under S2 Peptide Hormones, Growth Factors, Related Substances, and Mimetics (Prohibited List 2026). Researchers must ensure full institutional compliance before procurement or use. In vivo studies using MK-677 must comply with applicable IACUC requirements and institutional review procedures.

Recent FDA Enforcement Actions (2025–2026): The FDA issued a consumer alert in September 2025 regarding MK-677 in iKids-Growth products marketed for children, and initiated a recall of Agebox products containing undeclared ibutamoren in March 2026. These actions reflect ongoing FDA enforcement against unauthorized MK-677 consumer products and reinforce that research-grade material must never be represented as a consumer or dietary supplement product.

Where Do Researchers Source MK-677 Ibutamoren?

For lab-grade MK-677, researchers look for independently third-party tested batches with a Certificate of Analysis (COA) available per lot — confirming compound identity by HPLC, purity percentage, heavy metals panel, and absence of residual solvents and common contaminants. Given recent FDA enforcement actions against unauthorized MK-677 consumer products, sourcing from suppliers with traceable, batch-specific COA documentation is a baseline requirement for any compliant research program.

BehemothLabz supplies research-grade MK-677 Ibutamoren strictly for preclinical and in vitro research use. Each batch is supported by third-party COA documentation at stated purity, making it a go-to resource for laboratories requiring verified GH secretagogue compounds for standardized study protocols.

PureRawz also offers research-grade MK-677 Ibutamoren with independently verified purity certificates for laboratory procurement.

Disclosure: This article contains affiliate or sponsored links to BehemothLabz and/or PureRawz.co. Content is for informational purposes only and does not constitute medical advice or endorsement of any product for human use.

Conclusion

MK-677 Ibutamoren stands out among research compounds in the GH secretagogue class for its oral bioavailability (~60–70%), spiroindoline-based structural stability, well-characterized GHSR-1a binding profile (Ki ~0.4 nM), and an unusually substantial early investigational literature compared to most non-approved compounds. Research is still evolving, findings from human volunteer studies remain early-phase and exploratory, and long-term safety data are absent.

For researchers following the GH-axis modulation space, MK-677’s combination of oral delivery, ~24-hour half-life, defined Gq/PLC/IP3/calcium receptor cascade, and the documented 97% GH elevation in Chapman et al. makes it a frequently referenced tool compound in appropriately designed laboratory protocols — provided all IACUC, institutional, and regulatory compliance requirements are met. Cardiac risk, insulin sensitivity effects, and the FDA’s 2025–2026 enforcement actions against unauthorized MK-677 consumer products remain material considerations for any research ethics review.

For laboratories following this research, BehemothLabz offers COA-verified MK-677 Ibutamoren for preclinical laboratory use only.

Frequently Asked Questions About MK-677 Ibutamoren

What is MK-677 Ibutamoren, and how does it work? MK-677 (Ibutamoren) is a non-peptide spiroindoline-derived ghrelin receptor agonist that activates GHSR-1a via a Gq/PLC/IP3/calcium signaling cascade to stimulate pulsatile growth hormone release and downstream IGF-1 elevation in research models. It is orally bioavailable at approximately 60–70%, with a binding Ki of approximately 0.4 nM at the GHSR-1a receptor. It is not approved for human use and is intended strictly for laboratory research.

Is MK-677 a SARM? No. MK-677 is frequently grouped alongside SARMs in research discussions, but it is mechanistically distinct. SARMs are selective androgen receptor modulators. MK-677 is a growth hormone secretagogue — a ghrelin receptor agonist that works via the GH-IGF-1 axis and the Gq/PLC/IP3/calcium intracellular pathway, not the androgen receptor pathway. The two compound classes have entirely different molecular targets and mechanism profiles.

Is MK-677 approved by the FDA? No. MK-677 has not received FDA approval for any human or veterinary indication. Merck’s Phase II/III clinical program was halted before completion. The FDA has noted congestive heart failure risk concerns with sustained GH/IGF-1 axis activation and has taken enforcement action against unauthorized consumer MK-677 products in 2025–2026. It is not a dietary supplement, and its use is prohibited in competitive sport by WADA under S2 Peptide Hormones and Growth Factors (2026 List).

What does the research on MK-677 show? Published investigational studies have examined MK-677’s effects on GH pulsatility (including a reported 97% increase in mean 24-hour GH concentrations in Chapman et al. 1996), serum IGF-1 levels, body composition markers, nitrogen balance, bone turnover biomarkers, fat-free mass in obese subjects, and sleep architecture. All findings are early-phase or preclinical — they do not constitute approved efficacy data, and long-term safety data are absent.

How does MK-677 compare to peptide GH secretagogues like GHRP-6? MK-677 is orally bioavailable at ~60–70% and has a ~24-hour half-life, compared to GHRP-6, which requires injection and has a half-life of 15–60 minutes. Both act on GHSR-1a via the Gq/PLC/IP3/calcium signaling cascade, but MK-677’s spiroindoline scaffold provides structural stability that peptide sequences lack. Its longer receptor engagement window makes it more practical for standardized in vivo research protocols.

Is MK-677 legal to purchase for research in the United States? In the United States, MK-677 is not listed as a DEA-scheduled controlled substance, meaning it can be legally procured for legitimate laboratory research purposes. However, it is not approved for human use, is not sold as a dietary supplement, and is prohibited by WADA in sport. The FDA has taken enforcement actions against unauthorized consumer MK-677 products in 2025–2026. Regulatory status varies internationally — researchers must verify applicable jurisdiction laws before procurement.

What are the main risks of MK-677 in a laboratory setting? Key risk considerations include: potential insulin sensitivity effects and fasting glucose elevation documented in human volunteer studies; a documented cardiac adverse event in the Nass et al. 2008 study with FDA-noted congestive heart failure concerns; uncharacterized long-term GH-axis feedback disruption; IGF-1’s known mitogenic signaling properties and associated tumor promotion concerns; and mandatory IACUC compliance for in vivo protocols. Standard PPE and institutional biosafety protocols are mandatory for all handling.

Where can researchers source verified MK-677 Ibutamoren? Researchers typically source MK-677 from suppliers providing independent third-party Certificates of Analysis per batch, confirming HPLC purity, identity, and contaminant screening. BehemothLabz and PureRawz are among the suppliers known in the research compound community for COA-verified laboratory-grade MK-677.

References

1. Chapman IM, et al. (1996). Stimulation of the Growth Hormone (GH)-Insulin-Like Growth Factor I Axis by Daily Oral Administration of an Orally Active, Selective Agonist of the GH Secretagogue Receptor. Journal of Clinical Endocrinology & Metabolism, 81(12), 4249–4257. doi:10.1210/jcem.81.12.8954023. PMID: 8954023. https://pubmed.ncbi.nlm.nih.gov/8954023/
   
2. Nass R, et al. (2008). Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults. Annals of Internal Medicine, 149(9), 601–611. PMID: 18381496. https://pubmed.ncbi.nlm.nih.gov/18381496/
   
3. Murphy MG, et al. (1998). MK-0677, an Orally Active Growth Hormone Secretagogue, Reverses Diet-Induced Catabolism. Journal of Clinical Endocrinology & Metabolism, 83(2), 320–325. PMID: 9467542. https://pubmed.ncbi.nlm.nih.gov/9467542/
   
4. Svensson J, et al. (1998). Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure. Journal of Clinical Endocrinology & Metabolism, 83(2), 362–369. PMID: 9467549. https://pubmed.ncbi.nlm.nih.gov/9467549/
   
5. Murphy MG, et al. (1999). Oral Administration of the Growth Hormone Secretagogue MK-677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults. Journal of Bone and Mineral Research, 14(7), 1182–1188. PMID: 10404823. https://pubmed.ncbi.nlm.nih.gov/10404823/
   
6. World Anti-Doping Agency (WADA). Prohibited List 2026 — S2 Peptide Hormones, Growth Factors, Related Substances, and Mimetics. https://www.wada-ama.org/en/prohibited-list